- Previous Close
0.0900 - Open
0.0850 - Bid 0.0850 x --
- Ask 0.0950 x --
- Day's Range
0.0850 - 0.0900 - 52 Week Range
0.0700 - 0.1400 - Volume
29,300 - Avg. Volume
36,659 - Market Cap (intraday)
63.156M - Beta (5Y Monthly) 10.73
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Nov 26, 2024 - Dec 2, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Europe, the Asia Pacific, and internationally. The company offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and syphilis; and Miriad triple product to perform preliminary screening of HIV and hepatitis. It also provides Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics; and Reveal G4 HIV tests. In addition, the company offers VYRATM TriDemic antigen rapid test that distinguishes the three respiratory viruses, such as SARS-CoV-2, influenza, and respiratory syncytial virus that exhibit similar symptoms. It sells its products through a network of medical distributors and strategic business development partners to customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care clinics, governments, aid organizations, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of MedMira Holding AG.
www.medmira.com--
Full Time Employees
July 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: MIR.V
View More
Performance Overview: MIR.V
Trailing total returns as of 2024-11-08, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MIR.V
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MIR.V
View MoreValuation Measures
Market Cap
63.16M
Enterprise Value
69.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
164.08
Price/Book (mrq)
--
Enterprise Value/Revenue
180.27
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.45%
Return on Equity (ttm)
--
Revenue (ttm)
383.32k
Net Income Avi to Common (ttm)
-3.11M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
2.91M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.41M